Cargando…
Author Correction: Serum GFAP as a biomarker for disease severity in multiple sclerosis
Autores principales: | Abdelhak, A., Huss, A., Kassubek, J., Tumani, H., Otto, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548773/ https://www.ncbi.nlm.nih.gov/pubmed/31164658 http://dx.doi.org/10.1038/s41598-019-43990-1 |
Ejemplares similares
-
Serum GFAP as a biomarker for disease severity in multiple sclerosis
por: Abdelhak, A., et al.
Publicado: (2018) -
Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?
por: Abdelhak, Ahmed, et al.
Publicado: (2019) -
Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease
por: Huss, André, et al.
Publicado: (2022) -
Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies
por: Huss, André, et al.
Publicado: (2020) -
Author Correction: GFAP and desmin expression in lymphatic tissues leads to difficulties in distinguishing between glial and stromal cells
por: Günther, Hauke Simon, et al.
Publicado: (2021)